Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Rotavirus Prophylaxis Market Grown from 2024 to 2025?
The market for rotavirus prophylaxis has seen a swift expansion in the past few years. The sector, valued at $9.05 billion in 2024, is expected to reach $10.03 billion in 2025, representing a compound annual growth rate (CAGR) of 10.8%. The surge in growth during the historical timeframe can be linked to factors such as the accessibility and fairness of vaccines, the emergence of new rotavirus strains, research and development investment, and public health readiness.
What Growth Rate Is Anticipated for the Rotavirus Prophylaxis Market in the Coming Years?
The market for rotavirus prophylaxis is expected to witness robust growth in the coming years. The market is projected to reach up to $14.63 billion by 2029, expanding at a compound annual growth rate (CAGR) of 9.9%. Factors driving this predicted growth during the forecast period include the burden of gastrointestinal diseases, global expansion, vaccination campaigns, and vaccine confidence. Key trends anticipated during this forecast period are next-generation vaccines, mixed vaccines, innovative vaccine delivery methods, and worldwide immunization collaboration.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
Who Are the Leading Companies in the Rotavirus Prophylaxis Market?
Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
What Are the Key Drivers of the Rotavirus Prophylaxis Market?
The upward trend of vaccine courses is predicted to fuel the advancement of the rotavirus prophylaxis market. A vaccine course, which is a particular dosage created to offer protection against a specific illness, triggers an immunological response that provides superior protection against rotavirus infection. This heightened immunity lowers disease risk and enhances the overall effectiveness of the vaccine. UNICEF, an American humanitarian and developmental support entity for children, reported in January 2022 that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were produced in 2022, and they predict this figure may reach 9.31 million courses by 2028. Additionally, approximately 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with forecasted production telling it may rise to 6.13 million courses by 2028. Thus, the increasing vaccine course production will underpin the future growth of the rotavirus prophylaxis market. The Rotavirus Prophylaxis Market is driven by institutional funding which catalyzes its growth. Institutional funding, the allocation of resources in terms of money, effort or even time, for the financing needs of programs and projects, is expected to stimulate the growth of the rotavirus prophylaxis market. The growing number of rotavirus incidents has drawn substantial governmental and private sector funding. The funding serves to aid in the various stages of development of rotavirus vaccines and oral treatments. For instance, In April 2022, Indiana University, an American public research university, was awarded a $1.2 million grant by venture capital firm GIVAX Inc. for developing new technology for an oral rotavirus-norovirus vaccine designed for infants. This technology broadens the protection the currently available rotavirus vaccine provides to also include norovirus, a highly infectious virus known to cause extreme vomiting and diarrhoea in young children. Hence, the increase in available funding will further stimulate the growth of the rotavirus prophylaxis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp
What Are the Key Market Segments in the Rotavirus Prophylaxis Industry?
The rotavirus prophylaxis market covered in this report is segmented –
1) By Treatment: Rotarix, Rotavac, Rotavin-M1, Oral Rehydration Fluid, Other Treatments
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Rotarix: Single Dose, Multi-Dose
2) By Rotavac: Liquid Formulation, Freeze-Dried Formulation
3) By Rotavin-M1: Liquid Formulation, Freeze-Dried Formulation
4) By Oral Rehydration Fluid: Electrolyte Solutions, Glucose-Based Solutions
5) By Other Treatments: Supportive Care, Antidiarrheal Medications
What Are the Latest Trends in the Rotavirus Prophylaxis Market?
Major firms in the rotavirus prophylaxis industry are creating vaccines to fulfill customer needs. The approval of these vaccines is a vigorous process that encompasses several phases of development and testing. It is vital to ensure that these vaccines are both secure and efficacious in battling this viral infection, especially in infants and young children. For example, GlaxoSmithKline PLC, a pharmaceutical and biotech firm based in the UK, proclaimed in November 2022 that an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral) had been approved by the Food and Drug Administration (FDA). This prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants. This new oral-dosing applicator-only presentation is entirely a liquid solution that requires no reconstitution before usage. Both ROTARIX lyophilized and liquid formulations, given orally in a two-dose series, contain the same live, human-attenuated rotavirus strain and are produced using similar methods.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
What Are the Key Regional Markets in the Rotavirus Prophylaxis Industry?
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13045
This Report Delivers Insight On:
1. How big is the rotavirus prophylaxis market, and how is it changing globally?
2. Who are the major companies in the rotavirus prophylaxis market, and how are they performing?
3. What are the key opportunities and risks in the rotavirus prophylaxis market right now?
4. Which products or customer segments are growing the most in the rotavirus prophylaxis market?
5. What factors are helping or slowing down the growth of the rotavirus prophylaxis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model